Richard King

Richard King is a declared insider at 5 companies (chief executive); the most frequent names are KOS Pharmaceuticals Inc, Adamas Pharmaceuticals Inc and Talphera, Inc. Between 3 January 2006 and 30 June 2021, the trades on record add up to 19 filings.

The open-market side counts 1 purchase for €11k alongside 5 sales for €894k. Taken together, the sales exceed the purchases by €883k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 7 share grants and 3 option exercises.

The latest filing, published on 6 July 2021, reports a transaction of €18k in Spruce Biosciences, Inc. The most recent open-market purchase was published on 13 June 2011, 5,611 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.